Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer

Cancer Gene Therapy

Volumn 20, Issue 2, 2013, Pages 77-81

  Yin, X ^a   Yu, B ^a   Tang, Z ^b   He, B ^a   Ren, J ^a   Xiao, X ^a   Tang, W ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

apoptosis; Bifidobacterium infantis; gene therapy; HSV tk GCV

Indexed keywords

CASPASE 9; CYTOCHROME C; FAS ANTIGEN; FAS LIGAND; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIUM COLONY; BIFIDOBACTERIUM LONGUM INFANTIS; BLADDER CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HERPES SIMPLEX VIRUS; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; RAT; RECOMBINANT PLASMID; SUICIDE GENE THERAPY;

ANIMALS; APOPTOSIS; BIFIDOBACTERIUM; DISEASE MODELS, ANIMAL; GANCICLOVIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; NEOPLASMS, EXPERIMENTAL; RATS; SIGNAL TRANSDUCTION; SIMPLEXVIRUS; THYMIDINE KINASE; URINARY BLADDER NEOPLASMS;

BIFIDOBACTERIUM LONGUM BV. INFANTIS; RATTUS; RODENTIA; SIMPLEXVIRUS;

EID: 84874107892     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.86     Document Type: Article

References (30)

1. Pan JG, Zhou X, Zeng GW, Han RF. Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo. J Surg Oncol 2012; 105: 249-257.
2. Terao S, Shirakawa T, Goda K, Kamidono S, Fujisawa M, Gotoh A. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model. Anticancer Res 2005; 25: 2757-2760.
3. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
4. Argnani A, Leer RJ, van Luijk N, Pouwels PH. A convenient and reproducible method to genetically transform bacteria of the genus Bifidobacterium. Microbiology 1996; 142(Pt 1): 109-114.
5. Kohwi Y, Imai K, Tamura Z, Hashimoto Y. Antitumor effect of Bifidobacterium infantis in mice. Gann 1978; 69: 613-618.
6. Tang W, He Y, Zhou S, Ma Y, Liu G. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Cancer Res 2009; 28: 155.
7. Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 2005; 12: 133-140.
8. Fujimori M, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 2002; 5: 200-203.
9. Sasaki T, Fujimori M, Hamaji Y, Hama Y, Ito K, Amano J et al. Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci 2006; 97: 649-657.
10. Jenes A, Ruzsnavszky F, Telek A, Szigeti GP, Csernoch L. A possible role of the cholinergic and purinergic receptor interaction in the regulation of the rat urinary bladder function. J Muscle Res Cell Motil 2012; 32: 421-431.
11. Li CG, Li ML, Shu XH, Liu YJ, Wu WS. Antitumor effects of recombinant human interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis. Cancer Chemother Pharmacol 2010; 66: 981-986.
12. Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 1998; 160: 571-576.
13. Wolfe D, Mata M, Fink DJ. Targeted drug delivery to the peripheral nervous system using gene therapy. Neurosci Lett 2012; 527: 85-89.
14. Ruiz-Moyano S, Tao N, Underwood MA, Mills DA. Rapid discrimination of Bifidobacterium animalis subspecies by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Food Microbiol 2012; 30: 432-437.
15. Wei YX, Zhang ZY, Liu C, Malakar PK, Guo XK. Safety assessment of Bifidobacterium longum JDM301 based on complete genome sequences. World J Gastroenterol 2012; 18: 479-488.
16. Vaupel PW. Oxygenation of solid tumors. In: Teicher BA (ed). Drug Resistance in Oncology. Marcel Dekker: New York, pp 53-85, 1993.
17. Zhu H, Li Z, Mao S, Ma B, Zhou S, Deng L et al. Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium infantis on Lewis lung cancer in mice. Cancer Gene Ther 2011; 18: 884-896.
18. Hu B, Kou L, Li C, Zhu LP, Fan YR, Wu ZW et al. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther 2009; 16: 655-663.
19. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-170.
20. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008; 25: 462-466.
21. Maura D, Debarbieux L. Bacteriophages as twenty-first century antibacterial tools for food and medicine. Appl Microbiol Biotechnol 2011; 90: 851-859.
22. Chen Y, Wang G, Kong D, Zhang Z, Yang K, Liu R et al. Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer. Mol Carcinog 2011.
23. Alieva M, Bago JR, Aguilar E, Soler-Botija C, Vila OF, Molet J et al. Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS One 2012; 7: e35148.
24. Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res 2000; 60: 3212-3217.
25. Bai S, Du L, Liu W, Whittle IR, He L. Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem Biophys Res Commun 1999; 259: 455-459.
26. Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2702.
27. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28: 4-41.
28. Haynes P, Lambert TR, Mitchell ID. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat Res 1996; 369: 65-74.
29. Nicholas TW, Read SB, Burrows FJ, Kruse CA. Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol 2003; 18: 495-507.
30. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.